Europe
Even before a vaccine for the novel coronavirus has been completely developed, nations across the globe are jockeying for position to lay claim for the potential preventative medicine in something of a healthcare arms race.
A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.
Forbion, a European life sciences venture capital firm, announced today that it had closed its Forbion Growth Opportunities Fund at $208 million.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
They will focus on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such and rheumatoid arthritis.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
On Tuesday, the White House notified Congress and the United Nations of the decision. However, the withdrawal will not be immediate.
Kiadis Pharma, based in Amsterdam, The Netherlands, licensed a previously undisclosed K-NK0004 program to Paris-based Sanofi.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
PRESS RELEASES